288 related articles for article (PubMed ID: 26946190)
1. Risk of hepatocellular carcinoma after sustained virological response in Veterans with hepatitis C virus infection.
El-Serag HB; Kanwal F; Richardson P; Kramer J
Hepatology; 2016 Jul; 64(1):130-7. PubMed ID: 26946190
[TBL] [Abstract][Full Text] [Related]
2. Hepatocellular carcinoma risk decreases as time accrues following hepatitis C virus eradication.
Vutien P; Kim NJ; Moon AM; Johnson KM; Berry K; Green PK; Ioannou GN
Aliment Pharmacol Ther; 2024 Feb; 59(3):361-371. PubMed ID: 37955206
[TBL] [Abstract][Full Text] [Related]
3. Body mass index is associated with age-at-onset of HCV-infected hepatocellular carcinoma patients.
Akiyama T; Mizuta T; Kawazoe S; Eguchi Y; Kawaguchi Y; Takahashi H; Ozaki I; Fujimoto K
World J Gastroenterol; 2011 Feb; 17(7):914-21. PubMed ID: 21412500
[TBL] [Abstract][Full Text] [Related]
4. Effect of previous infection with hepatitis B virus on the incidence of hepatocellular carcinoma after sustained virologic response in patients with chronic hepatitis C virus infection.
Toyoda H; Koshiyama Y; Yasuda S; Kumada T; Chayama K; Akita T; Tanaka J
J Viral Hepat; 2024 Mar; 31(3):137-142. PubMed ID: 38146596
[TBL] [Abstract][Full Text] [Related]
5. Development and validation of a nomogram for assessing hepatocellular carcinoma risk after SVR in hepatitis C patients with advanced fibrosis and cirrhosis.
Xu S; Qiu L; Xu L; Liu Y; Zhang J
Infect Agent Cancer; 2024 Apr; 19(1):17. PubMed ID: 38664813
[TBL] [Abstract][Full Text] [Related]
6. Screening and risk of hepatocellular carcinoma in patients with advanced fibrosis after hepatitis C virus eradication.
Espina Cadena S; Casas Deza D; Julián Gomara B; Borao Laguna CV; Sierra Gabarda O; Lamuela Calvo LJ; Lorente S; Serrano T; Arbonés Mainar JM; Bernal Monterde V
Rev Esp Enferm Dig; 2024 Jan; ():. PubMed ID: 38214165
[TBL] [Abstract][Full Text] [Related]
7. Impending HCC diagnosis in patients with cirrhosis after HCV cure features a natural killer cell signature.
Engelskircher SA; Chen PC; Strunz B; Oltmanns C; Ristic T; Owusu Sekyere S; Kraft ARM; Cornberg M; Wirth T; Heinrich B; Björkström NK; Wedemeyer H; Woller N
Hepatology; 2024 Feb; ():. PubMed ID: 38381525
[TBL] [Abstract][Full Text] [Related]
8. Validation of SMART Model for HCC Risk stratification in genotype -4 HCV Patients following SVR and its comparison with GES score.
Shiha G; Mikhail N; Soliman R
J Hepatol; 2024 May; ():. PubMed ID: 38759890
[No Abstract] [Full Text] [Related]
9. Promise and pitfalls of a natural killer cell signature for HCC detection in patients with HCV with sustained virological response.
Moctezuma-Velazquez C; Wong YJ; Montano-Loza AJ
Hepatology; 2024 Feb; ():. PubMed ID: 38353564
[No Abstract] [Full Text] [Related]
10. Early occurrence and recurrence of hepatocellular carcinoma in HCV-related cirrhosis treated with direct-acting antivirals.
Conti F; Buonfiglioli F; Scuteri A; Crespi C; Bolondi L; Caraceni P; Foschi FG; Lenzi M; Mazzella G; Verucchi G; Andreone P; Brillanti S
J Hepatol; 2016 Oct; 65(4):727-733. PubMed ID: 27349488
[TBL] [Abstract][Full Text] [Related]
11. Risk of Hepatocellular Cancer in HCV Patients Treated With Direct-Acting Antiviral Agents.
Kanwal F; Kramer J; Asch SM; Chayanupatkul M; Cao Y; El-Serag HB
Gastroenterology; 2017 Oct; 153(4):996-1005.e1. PubMed ID: 28642197
[TBL] [Abstract][Full Text] [Related]
12. Unexpected high rate of early tumor recurrence in patients with HCV-related HCC undergoing interferon-free therapy.
Reig M; Mariño Z; Perelló C; Iñarrairaegui M; Ribeiro A; Lens S; Díaz A; Vilana R; Darnell A; Varela M; Sangro B; Calleja JL; Forns X; Bruix J
J Hepatol; 2016 Oct; 65(4):719-726. PubMed ID: 27084592
[TBL] [Abstract][Full Text] [Related]
13. Hepatocellular carcinoma risk following direct-acting antiviral HCV therapy: A systematic review, meta-analyses, and meta-regression.
Waziry R; Hajarizadeh B; Grebely J; Amin J; Law M; Danta M; George J; Dore GJ
J Hepatol; 2017 Dec; 67(6):1204-1212. PubMed ID: 28802876
[TBL] [Abstract][Full Text] [Related]
14. HCV eradication induced by direct-acting antiviral agents reduces the risk of hepatocellular carcinoma.
Ioannou GN; Green PK; Berry K
J Hepatol; 2017 Sep; ():. PubMed ID: 28887168
[TBL] [Abstract][Full Text] [Related]
15. Lack of evidence of an effect of direct-acting antivirals on the recurrence of hepatocellular carcinoma: Data from three ANRS cohorts.
ANRS collaborative study group on hepatocellular carcinoma (ANRS CO22 HEPATHER, CO12 CirVir and CO23 CUPILT cohorts). Electronic address: stanislas.pol@aphp.fr
J Hepatol; 2016 Oct; 65(4):734-740. PubMed ID: 27288051
[TBL] [Abstract][Full Text] [Related]
16. Eradication of Hepatitis C Virus Infection in Patients With Cirrhosis Reduces Risk of Liver and Non-Liver Complications.
Nahon P; Bourcier V; Layese R; Audureau E; Cagnot C; Marcellin P; Guyader D; Fontaine H; Larrey D; De Lédinghen V; Ouzan D; Zoulim F; Roulot D; Tran A; Bronowicki JP; Zarski JP; Leroy V; Riachi G; Calès P; Péron JM; Alric L; Bourlière M; Mathurin P; Dharancy S; Blanc JF; Abergel A; Serfaty L; Mallat A; Grangé JD; Attali P; Bacq Y; Wartelle C; Dao T; Benhamou Y; Pilette C; Silvain C; Christidis C; Capron D; Bernard-Chabert B; Zucman D; Di Martino V; Thibaut V; Salmon D; Ziol M; Sutton A; Pol S; Roudot-Thoraval F;
Gastroenterology; 2017 Jan; 152(1):142-156.e2. PubMed ID: 27641509
[TBL] [Abstract][Full Text] [Related]
17. Long-term effect of sustained virological response on hepatocellular carcinoma in patients with hepatitis C in Canada.
Janjua NZ; Chong M; Kuo M; Woods R; Wong J; Yoshida EM; Sherman M; Butt ZA; Samji H; Cook D; Yu A; Alvarez M; Tyndall M; Krajden M
J Hepatol; 2017 Mar; 66(3):504-513. PubMed ID: 27818234
[TBL] [Abstract][Full Text] [Related]
18. Hepatocellular carcinoma decreases the chance of successful hepatitis C virus therapy with direct-acting antivirals.
Prenner SB; VanWagner LB; Flamm SL; Salem R; Lewandowski RJ; Kulik L
J Hepatol; 2017 Jun; 66(6):1173-1181. PubMed ID: 28161470
[TBL] [Abstract][Full Text] [Related]
19. Epidemiology and outcomes of hepatitis C infection in elderly US Veterans.
El-Serag HB; Kramer J; Duan Z; Kanwal F
J Viral Hepat; 2016 Sep; 23(9):687-96. PubMed ID: 27040447
[TBL] [Abstract][Full Text] [Related]
20. Changes in patient backgrounds may increase the incidence of HCC after SVR in the era of IFN-free therapy for HCV.
Toyoda H; Kumada T; Tada T
Hepatology; 2016 Nov; 64(5):1818-1819. PubMed ID: 27136189
[No Abstract] [Full Text] [Related]
[Next] [New Search]
